Eximias Pharmaceutical Corporation

Principal investigators named for Thymitaq ETHECC(C) trial

Published in Lab Law Weekly, June 4th, 2004

Eximias Pharmaceutical Corporation announced the appointment of the coprincipal investigators for their pivotal phase III ETHECC(C) trial (Evaluation of Thymitaq nolatrexed dihydrochloride, in Unresectable Hepatocellular Carcinoma).

Robert G. Gish, MD, medical director of the liver transplant program at California Pacific Medical Center in San Francisco and Yehuda Z. Patt, MD, chief of gastrointestinal medical oncology at the Greenebaum Cancer Center of the University of Maryland have both accepted the Co-Principal Investigator positions for the ETHECC(C) trial. The decision came during the Eximias worldwide Thymitaq ETHECC(C) Trial Clinical Investigators Meeting in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2004-06-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry